{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:16:07Z","timestamp":1767485767619,"version":"3.48.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82160039"],"award-info":[{"award-number":["82160039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82160039"],"award-info":[{"award-number":["82160039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82160039"],"award-info":[{"award-number":["82160039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82160039"],"award-info":[{"award-number":["82160039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82160039"],"award-info":[{"award-number":["82160039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Guangxi Natural Science Foundation","award":["2025GXNSFAA069052"],"award-info":[{"award-number":["2025GXNSFAA069052"]}]},{"name":"the Guangxi Natural Science Foundation","award":["2025GXNSFAA069052"],"award-info":[{"award-number":["2025GXNSFAA069052"]}]},{"name":"the Guangxi Natural Science Foundation","award":["2025GXNSFAA069052"],"award-info":[{"award-number":["2025GXNSFAA069052"]}]},{"name":"the Guangxi Natural Science Foundation","award":["2025GXNSFAA069052"],"award-info":[{"award-number":["2025GXNSFAA069052"]}]},{"name":"the Guangxi Natural Science Foundation","award":["2025GXNSFAA069052"],"award-info":[{"award-number":["2025GXNSFAA069052"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06522-8","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T02:00:19Z","timestamp":1765245619000},"page":"6403-6410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Olverembatinib for 8p11 myeloproliferative syndrome with a positive BCR-FGFR1 fusion gene: a case report"],"prefix":"10.1007","volume":"104","author":[{"given":"Man","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"issue":"9","key":"6522_CR1","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.11406\/rinketsu.60.1157","volume":"60","author":"K Kirito","year":"2019","unstructured":"Kirito K (2019) [The 8p11 myeloproliferative syndrome: a review of recent literature]. Rinsho Ketsueki 60(9):1157\u20131165. https:\/\/doi.org\/10.11406\/rinketsu.60.1157","journal-title":"Rinsho Ketsueki"},{"issue":"1","key":"6522_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4103\/0366-6999.147863","volume":"128","author":"H Chao","year":"2015","unstructured":"Chao H, Zhou M, Zhang R (2015) A case with ZNF198-FGFR1 gene rearrangement presenting as acute eosinophil myeloid leukemia. Chin Med J (Engl) 128(1):131\u2013132. https:\/\/doi.org\/10.4103\/0366-6999.147863","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"6522_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/ng0198-84","volume":"18","author":"S Xiao","year":"1998","unstructured":"Xiao S, Nalabolu SR, Aster JC et al (1998) FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia\/lymphoma syndrome. Nat Genet 18(1):84\u201387. https:\/\/doi.org\/10.1038\/ng0198-84","journal-title":"Nat Genet"},{"issue":"6","key":"6522_CR4","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3324\/haematol.2010.036558","volume":"96","author":"B Wasag","year":"2011","unstructured":"Wasag B, Lierman E, Meeus P, Cools J, Vandenberghe P (2011) The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia\/lymphoma and t(7;8)(q22;p11). Haematologica 96(6):922\u2013926. https:\/\/doi.org\/10.3324\/haematol.2010.036558","journal-title":"Haematologica"},{"issue":"5","key":"6522_CR5","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/sj.leu.2403347","volume":"18","author":"EK Grand","year":"2004","unstructured":"Grand EK, Chase AJ, Heath C, Rahemtulla A, Cross NCP (2004) Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 18(5):962\u2013966. https:\/\/doi.org\/10.1038\/sj.leu.2403347","journal-title":"Leukemia"},{"issue":"10","key":"6522_CR6","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1182\/blood-2007-02-074286","volume":"110","author":"A Chase","year":"2007","unstructured":"Chase A, Grand FH, Cross NCP (2007) Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 110(10):3729\u20133734. https:\/\/doi.org\/10.1182\/blood-2007-02-074286","journal-title":"Blood"},{"key":"6522_CR7","doi-asserted-by":"publisher","first-page":"1320641","DOI":"10.3389\/fphar.2023.1320641","volume":"14","author":"J Ding","year":"2023","unstructured":"Ding J, Li W (2023) Case report: Olverembatinib monotherapy: the chemotherapy-free regimen for an elderly patient with relapsed Ph-positive acute lymphoblastic leukemia. Front Pharmacol 14:1320641. https:\/\/doi.org\/10.3389\/fphar.2023.1320641","journal-title":"Front Pharmacol"},{"issue":"14","key":"6522_CR8","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1002\/cam4.4041","volume":"10","author":"K Jiang","year":"2021","unstructured":"Jiang K, Tang X, Guo J et al (2021) GZD824 overcomes FGFR1-V561F\/M mutant resistance in vitro and in vivo. Cancer Med 10(14):4874\u20134884. https:\/\/doi.org\/10.1002\/cam4.4041","journal-title":"Cancer Med"},{"issue":"4","key":"6522_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100766","volume":"13","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang L, Tang X et al (2020) GZD824 as a FLT3, FGFR1 and PDGFR\u03b1 inhibitor against leukemia in vitro and in vivo. Transl Oncol 13(4):100766. https:\/\/doi.org\/10.1016\/j.tranon.2020.100766","journal-title":"Transl Oncol"},{"issue":"3","key":"6522_CR10","first-page":"83","volume":"102","author":"E Sabattini","year":"2010","unstructured":"Sabattini E, Bacci F, Sagramoso C, Pileri SA (2010) WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 102(3):83\u201387","journal-title":"Pathologica"},{"issue":"20","key":"6522_CR11","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"11","key":"6522_CR12","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"issue":"1","key":"6522_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1006\/geno.1998.5634","volume":"55","author":"S Kulkarni","year":"1999","unstructured":"Kulkarni S, Reiter A, Smedley D, Goldman JM, Cross NC (1999) The genomic structure of ZNF198 and location of breakpoints in the t(8;13) myeloproliferative syndrome. Genomics 55(1):118\u2013121. https:\/\/doi.org\/10.1006\/geno.1998.5634","journal-title":"Genomics"},{"issue":"3","key":"6522_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/s1535-6108(04)00053-4","volume":"5","author":"S Roumiantsev","year":"2004","unstructured":"Roumiantsev S, Krause DS, Neumann CA et al (2004) Distinct stem cell myeloproliferative\/t lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 5(3):287\u2013298. https:\/\/doi.org\/10.1016\/s1535-6108(04)00053-4","journal-title":"Cancer Cell"},{"issue":"2","key":"6522_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/10428194.2019.1660975","volume":"61","author":"R Manur","year":"2020","unstructured":"Manur R, Sung PJ, Loren AW et al (2020) Leukemic lineage switch in a t(8;22)(p11.2;q11.2)\/BCR-FGFR1-rearranged myeloid\/lymphoid neoplasm with RUNX1 mutation - diagnostic pitfalls and clinical management including FGFR1 inhibitor Pemigatinib. Leuk Lymphoma 61(2):450\u2013454. https:\/\/doi.org\/10.1080\/10428194.2019.1660975","journal-title":"Leuk Lymphoma"},{"key":"6522_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.humpath.2017.05.008","volume":"65","author":"X Montenegro-Garreaud","year":"2017","unstructured":"Montenegro-Garreaud X, Miranda RN, Reynolds A et al (2017) Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)\/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase. Hum Pathol 65:147\u2013156. https:\/\/doi.org\/10.1016\/j.humpath.2017.05.008","journal-title":"Hum Pathol"},{"issue":"2","key":"6522_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/med.21288","volume":"34","author":"M Katoh","year":"2014","unstructured":"Katoh M, Nakagama H (2014) FGF receptors: cancer biology and therapeutics. Med Res Rev 34(2):280\u2013300. https:\/\/doi.org\/10.1002\/med.21288","journal-title":"Med Res Rev"},{"issue":"5","key":"6522_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X et al (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5):401\u2013412. https:\/\/doi.org\/10.1016\/j.ccr.2009.09.028","journal-title":"Cancer Cell"},{"issue":"1","key":"6522_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3324\/haematol.2012.066407","volume":"98","author":"A Chase","year":"2013","unstructured":"Chase A, Bryant C, Score J, Cross NCP (2013) Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica 98(1):103\u2013106. https:\/\/doi.org\/10.3324\/haematol.2012.066407","journal-title":"Haematologica"},{"issue":"4","key":"6522_CR20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/leu.2015.136","volume":"30","author":"MS Khodadoust","year":"2016","unstructured":"Khodadoust MS, Luo B, Medeiros BC et al (2016) Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia 30(4):947\u2013950. https:\/\/doi.org\/10.1038\/leu.2015.136","journal-title":"Leukemia"},{"issue":"9","key":"6522_CR21","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1080\/10428194.2023.2226277","volume":"64","author":"Y Yan","year":"2023","unstructured":"Yan Y, Qu Shiqiang, Liu Jinqin et al (2023) Olverembatinib for myeloid\/lymphoid neoplasm associated with eosinophilia and FGFR1 rearrangement. Leuk Lymphoma 64(9):1605\u20131610. https:\/\/doi.org\/10.1080\/10428194.2023.2226277","journal-title":"Leuk Lymphoma"},{"key":"6522_CR22","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1182\/blood-2024-200003","volume":"144","author":"S Chen","year":"2024","unstructured":"Chen S, Wu D, Cai W et al (2024) A phase 2 study of olverembatinib for the treatment of myeloid\/lymphoid neoplasms with FGFR1 rearrangement. Blood 144:1781. https:\/\/doi.org\/10.1182\/blood-2024-200003","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06522-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06522-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06522-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:15:16Z","timestamp":1767485716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06522-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6522"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06522-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki, with protocols approved by institutional review boards (NO. 2024-E769-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Written informed consent was obtained from the patient for their clinical information to be used for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}